Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems - PubMed (original) (raw)
Comparative Study
. 1996 Feb 1;56(3):556-62.
Affiliations
- PMID: 8564971
Comparative Study
Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems
P Perego et al. Cancer Res. 1996.
Abstract
P53 status may be a determinant of chemosensitivity of tumor cells; however, its involvement in cellular resistance to cisplatin remains uncertain. To investigate the relationships between p53 and the development of resistance to cisplatin, the p53 gene status was studied in ovarian carcinoma cell systems which included two cisplatin-resistant variants (IGROV-1/Pt 0.5 and IGROV-1/Pt 1) selected in vitro after prolonged drug exposure of the cisplatin-sensitive parental IGROV-1 cell line. IGROV-1/Pt 0.5 and IGROV-1/Pt 1 cell lines exhibited a degree of resistance of approximately 6 and 14, respectively, following 96-h exposure to the drug and were cross-resistant to other DNA-damaging agents (ionizing radiation and melphalan). Resistance to cisplatin paralleled a reduced cell susceptibility to cisplatin-induced apoptosis. DNA single-strand conformation polymorphism analysis of exons 5-9 demonstrated the presence of two mutants alleles at exon 8 in the two resistant cell lines, in contrast to the parental IGROV-1 cell line which exhibited the wild-type p53 gene. Direct DNA sequencing revealed that the mutations consist of two nucleotide changes in the DNA-binding domain at codons 270 (T/A) and 282 (C/T). The consecutive levels of p53 protein were lower in IGROV-1 than in IGROV-1/Pt cells. Following exposure to ionizing radiation or cisplatin, accumulation of the p53 protein was markedly enhanced only in the sensitive cells. Concomitantly, the expression of WAF-1 protein was strongly induced in the parental IGROV-1 cells, whereas WAF-1 protein remained undetectable in the IGROV-1/Pt 1 subline after DNA-damaging treatment. Consistent with this finding is the observation that ionizing radiation caused a different pattern of cell cycle perturbation in sensitive and resistant cells. Northern blot analysis demonstrated a marked reduction in bax mRNA levels in IGROV-1/Pt 1 cisplatin-resistant cells. Cotransfection assays with wild-type or mutant p53 expression plasmids and a reporter gene plasmid that utilized the bax gene promoter to drive transcription of chloramphenicol acetyltransferase were consistent with the role of p53 in regulation of bax expression in these cells. Taken together, these observations support a role for mutations of the p53 gene in the development of cisplatin resistance in ovarian cancer as a consequence of loss of the ability of p53 to transactivate bax, an apoptosis-inducing gene.
Similar articles
- Emergence of p53 mutant cisplatin-resistant ovarian carcinoma cells following drug exposure: spontaneously mutant selection.
Righetti SC, Perego P, Corna E, Pierotti MA, Zunino F. Righetti SC, et al. Cell Growth Differ. 1999 Jul;10(7):473-8. Cell Growth Differ. 1999. PMID: 10437915 - Time-dependent changes in factors involved in the apoptotic process in human ovarian cancer cells as a response to cisplatin.
Kolfschoten GM, Hulscher TM, Schrier SM, van Houten VM, Pinedo HM, Boven E. Kolfschoten GM, et al. Gynecol Oncol. 2002 Mar;84(3):404-12. doi: 10.1006/gyno.2001.6537. Gynecol Oncol. 2002. PMID: 11855878 - Normal p53 status and function despite the development of drug resistance in human breast cancer cells.
Wosikowski K, Regis JT, Robey RW, Alvarez M, Buters JT, Gudas JM, Bates SE. Wosikowski K, et al. Cell Growth Differ. 1995 Nov;6(11):1395-403. Cell Growth Differ. 1995. PMID: 8562478 - p53 gene status and chemosensitivity in ovarian cancer.
Kigawa J, Sato S, Shimada M, Takahashi M, Itamochi H, Kanamori Y, Terakawa N. Kigawa J, et al. Hum Cell. 2001 Sep;14(3):165-71. Hum Cell. 2001. PMID: 11774736 Review. - Apoptosis and cancer chemotherapy.
Hickman JA, Potten CS, Merritt AJ, Fisher TC. Hickman JA, et al. Philos Trans R Soc Lond B Biol Sci. 1994 Aug 30;345(1313):319-25. doi: 10.1098/rstb.1994.0112. Philos Trans R Soc Lond B Biol Sci. 1994. PMID: 7846129 Review.
Cited by
- Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2.
Schuyer M, van der Burg ME, Henzen-Logmans SC, Fieret JH, Klijn JG, Look MP, Foekens JA, Stoter G, Berns EM. Schuyer M, et al. Br J Cancer. 2001 Nov 2;85(9):1359-67. doi: 10.1054/bjoc.2001.2101. Br J Cancer. 2001. PMID: 11720475 Free PMC article. - Number of apoptotic cells as a prognostic marker in invasive breast cancer.
de Jong JS, van Diest PJ, Baak JP. de Jong JS, et al. Br J Cancer. 2000 Jan;82(2):368-73. doi: 10.1054/bjoc.1999.0928. Br J Cancer. 2000. PMID: 10646890 Free PMC article. - p53-Dependent Anti-Proliferative and Pro-Apoptotic Effects of a Gold(I) _N_-Heterocyclic Carbene (NHC) Complex in Colorectal Cancer Cells.
Dabiri Y, Abu El Maaty MA, Chan HY, Wölker J, Ott I, Wölfl S, Cheng X. Dabiri Y, et al. Front Oncol. 2019 May 29;9:438. doi: 10.3389/fonc.2019.00438. eCollection 2019. Front Oncol. 2019. PMID: 31231607 Free PMC article. - Deubiquitinases in Ovarian Cancer: Role in Drug Resistance and Tumor Aggressiveness.
Beretta GL, Costantino M, Mirra L, Pettinari P, Perego P. Beretta GL, et al. Int J Biol Sci. 2024 Sep 23;20(13):5208-5222. doi: 10.7150/ijbs.100355. eCollection 2024. Int J Biol Sci. 2024. PMID: 39430244 Free PMC article. Review. - NOXA-induced alterations in the Bax/Smac axis enhance sensitivity of ovarian cancer cells to cisplatin.
Lin C, Zhao XY, Li L, Liu HY, Cao K, Wan Y, Liu XY, Nie CL, Liu L, Tong AP, Deng HX, Li J, Yuan Z, Wei YQ. Lin C, et al. PLoS One. 2012;7(5):e36722. doi: 10.1371/journal.pone.0036722. Epub 2012 May 9. PLoS One. 2012. PMID: 22590594 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials
Miscellaneous